抗凝疗可能降低亚细分非封闭性下静脉卡瓦过器相关的血栓负担:单中心机构的回顾性研究
Pengkai Cao1, Xintong Luo2, Yunsong Li1
1Vascular Surgery Department of Third Hospital of Hebei Medical University, Shijiazhuang, China.
概括
抗凝固疗法有效地减少了与过器相关的血栓负担. 较长的抗凝期和上下静脉膜镜的放置改善了血栓分辨率,可能提高了镜检索率.
科学领域:
- 血管外科 血管外科
- 干预性放射学 干预性放射学
- 心血管医学 心血管医学
背景情况:
- 下腔静脉过器 (IVCF) 用于预防肺栓塞.
- 过器相关的血栓可能会使IVCF管理和检索复杂化.
- 亚细分非闭塞性血栓是一种特定类型的IVCF相关并发症.
研究的目的:
- 评估抗凝治疗对细分非闭合性过器相关血栓的疗效.
- 为了确定影响血栓体积变化的风险因素.
- 根据IVCF位置 (内与上) 来评估结果.
主要方法:
- 对IVCF安置和检索患者的一项回顾性单中心研究 (2018年7月 - 2023年12月).
- 纳入标准:细分的非包容性过器相关的血栓.
- 收集的数据:人口统计,病史,IVCF细节,抗凝时间和结果.
主要成果:
- 研究了两个组:下内IVCF (n=32) 和上内IVCF (n=38).
- 在去除IVCF之前,上的组具有显著更长的抗凝时间 (74.47 vs 51.25天).
- 在上小组中,血栓分辨率更高 (38/38完全/部分 vs. 29/32在下小组);下小组有3例进展的血栓.
结论:
- 抗凝固疗法有效地减少了与过器相关的血栓负担.
- 较长的抗凝时间和上IVCF放置与更好的血栓分辨率有关.
- 结果表明,有了更好的选择来管理与过器相关的血栓和可能更高的IVCF检索率.
相关概念视频
Venous Thrombosis III: Interprofessional Care
254
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
254
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
262
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
262
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
267
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
267
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis I: Introduction
245
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
245
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K


